A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

about

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

Item

http://www.wikidata.org/entity/Q49886531

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A Phase I Trial of the PI3K In ...... With Metastatic Breast Cancer.

@en

A Phase I Trial of the PI3K In ...... With Metastatic Breast Cancer.

@nl

type

Item

label

A Phase I Trial of the PI3K In ...... With Metastatic Breast Cancer.

@en

A Phase I Trial of the PI3K In ...... With Metastatic Breast Cancer.

@nl

prefLabel

A Phase I Trial of the PI3K In ...... With Metastatic Breast Cancer.

@en

A Phase I Trial of the PI3K In ...... With Metastatic Breast Cancer.

@nl

P1476

A Phase I Trial of the PI3K In ...... With Metastatic Breast Cancer.

@en

P2093

Autumn J McRee

http://www.w3.org/2001/XMLSchema#string

Carey K Anders

http://www.w3.org/2001/XMLSchema#string

Dominic T Moore

http://www.w3.org/2001/XMLSchema#string

E Claire Dees

http://www.w3.org/2001/XMLSchema#string

Karen E Weck

http://www.w3.org/2001/XMLSchema#string

Katherine Reeder-Hayes

http://www.w3.org/2001/XMLSchema#string

Lisa A Carey

http://www.w3.org/2001/XMLSchema#string

Paul K Marcom

http://www.w3.org/2001/XMLSchema#string

Rachel Phipps

http://www.w3.org/2001/XMLSchema#string

William C Zamboni

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Repeated observation of breast tumor subtypes in independent gene expression data sets

Supervised risk predictor of breast cancer based on intrinsic subtypes

A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

PTEN function in normal and neoplastic growth.

P31

scholarly article

P356

10.1016/J.CLBC.2017.10.014

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Charles M. Perou

P577

2017-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29153866

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

5924643

http://www.w3.org/2001/XMLSchema#string